Human Papillomavirus (HPV)
16
3
3
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.3%
1 terminated out of 16 trials
87.5%
+0.9% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (16)
Effect of HPV Education on Women's Knowledge
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV
The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions
The Role of Circulating Tumour DNA in Head and Neck Cancer
Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer
Primary HPV Self-Collection in Indonesia
Perception, Awareness, and Acceptance of Human Papillomavirus Disease and Vaccine Among Parents of Boys Aged 9 to 18 Years
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics
New Strategies to Assess Anal Cancer Risk In Women
Prevalence of HPV Transmission During Medically Assisted Procreation Procedures
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
AMG 319 in HPV Positive and Negative HNSCC